G Sridhar Prasad
Dr. G. Sridhar Prasad is the co-founder and VP of Research of CalAsia Pharmaceuticals. He has been the core member of multiple drug discovery teams, including the marketed drug, NESINA (Alogliptin, DPPIV Inhibitor) and clinical candidate MK-4965, for the treatment of HIV-1 AIDS. He obtained his Ph.D., from Indian Institute of Science, Bangalore, India and post-doctoral training at University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he grew to the ranks of Assistant Professor. He has co-authored over 45 peer reviewed research articles, holds six US and international patents. He serves on the editorial board of Current Protein and Peptide Science.